CytoMed Therapeutics (GDTC) Depreciation & Amortization - Total (2022 - 2025)

CytoMed Therapeutics has disclosed Depreciation & Amortization - Total across 4 years of filings, most recently posting $84490.0 for Q2 2025.

• In Q2 2025, Depreciation & Amortization - Total fell 29.82% year-over-year to $84490.0; the TTM figure through Jun 2025 stood at $479979.0 (changed N/A YoY), while the FY2025 annual figure was -$196896.0, down 79.25% from the prior year.
• Depreciation & Amortization - Total came in at $84490.0 for Q2 2025 at CytoMed Therapeutics, down from $120399.0 in the prior quarter.
• In the past five years, Depreciation & Amortization - Total ranged from a high of $146758.0 in Q2 2023 to a low of $84490.0 in Q2 2025.
• Average Depreciation & Amortization - Total over 4 years is $119994.8, with a median of $124365.5 recorded in 2022.
• Year-over-year, Depreciation & Amortization - Total grew 14.36% in 2023 and fell 29.82% in 2025.
• Over 4 years, Depreciation & Amortization - Total stood at $128332.0 in 2022, then climbed by 14.36% to $146758.0 in 2023, then declined by 17.96% to $120399.0 in 2024, then decreased by 29.82% to $84490.0 in 2025.
• Per Business Quant data, the three most recent Depreciation & Amortization - Total figures were $84490.0 in Q2 2025, $120399.0 in Q2 2024, and $146758.0 in Q2 2023.